论文部分内容阅读
目的 探讨P2 7蛋白表达与骨肉瘤临床病理、肿瘤细胞增殖活性及其与预后的关系。方法 应用S P免疫组化法检测 80例骨肉瘤P2 7蛋白及增殖细胞核抗原 (PCNA)的表达 ,计算其标记指数 (Labelingindex ,LI)。结果 p2 7LI在 0 %～ 97.5 %之间 ,PCNALI在 9%～ 98%之间 ,而在正常骨及良性骨瘤中不见表达。P2 7蛋白表达与骨肉瘤Dahlin分型、Price分级无关 ,而与WHO分型、PCNALI密切相关。生存率分析显示 ,p2 7LI <48.4%的骨肉瘤预后较好 ,LI >48.4%的骨肉瘤预后较差。结论 骨肉瘤P2 7蛋白表达与肿瘤细胞增殖活性及生存率密切相关 ,其表达对骨肉瘤诊断和预后评估可能具有重要价值
Objective To investigate the relationship between the expression of P2 7 protein and the clinicopathology, tumor cell proliferative activity and prognosis of osteosarcoma. Methods The expression of P2 7 protein and proliferating cell nuclear antigen (PCNA) in 80 cases of osteosarcoma were detected by SP immunohistochemistry. Labeling index (LI) was calculated. Results p2 7LI was between 0% and 97.5% and PCNALI between 9% and 98%, but not between normal bone and benign osteoma. P2 7 protein expression and osteosarcoma Dahlin type, Price classification has nothing to do, but with the WHO classification, PCNALI are closely related. Survival analysis showed that the prognosis of osteosarcoma with p2 7LI <48.4% was good, and the prognosis of osteosarcoma with LI> 48.4% was poor. Conclusion The expression of P2 7 in osteosarcoma is closely related to the proliferation of tumor cells and the survival rate of osteosarcoma, which may have important value in the diagnosis and prognosis of osteosarcoma